IL1B and lung carcinoma: IL-1α blockade delayed lung cancer progression more robustly than IL-1β blockade (Fig. 4G); notably, though, the combination of both exhibited an apparent synergistic effect in reducing tumor growth that was comparable to treating mice with anakinra (Fig. 4G).